SCHEMBL23933988

SCHEMBL23933988

CCOc1ccc(S(=O)(=O)Nc2cccc3ccc(C)nc23)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.71
KMT2A Q03164 3/20 0.71
MEN1 O00255 2/20 0.71
SLC40A1 Q9NP59 5/20 0.69
GLO1 Q04760 3/20 0.69
AGTR1 P30556 2/20 0.69
PAX8 Q06710 1/20 0.69
LMNA P02545 3/20 0.59
NPSR1 Q6W5P4 2/20 0.59
RELA Q04206 6/20 0.57
NFKBIA P25963 6/20 0.57
SQSTM1 Q13501 1/20 0.56
KEAP1 Q14145 1/20 0.56
NFE2L2 Q16236 1/20 0.56
HTT P42858 2/20 0.55
KDM4E B2RXH2 1/20 0.55
NPC1 O15118 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 2/20 0.54
MITF O75030 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26053588 0.83 KMT2A (1.00) TDP1KMT2AMEN1SLC40A1GLO1
SCHEMBL18889904 0.83 KMT2A (0.71) TDP1KMT2AMEN1SLC40A1GLO1
SCHEMBL6984645 0.82 SLC40A1 (1.00) TDP1KMT2AMEN1SLC40A1GLO1
SCHEMBL23933986 0.81 KMT2A (0.74) TDP1KMT2AMEN1SLC40A1GLO1
SCHEMBL23934034 0.79 KMT2A (0.76) TDP1KMT2AMEN1SLC40A1GLO1
SCHEMBL23934032 0.79 KMT2A (0.76) TDP1KMT2AMEN1SLC40A1GLO1
SCHEMBL22578645 0.78 KMT2A (0.74) TDP1KMT2AMEN1SLC40A1GLO1
SCHEMBL28109026 0.77 KEAP1 (0.72) TDP1KMT2AMEN1LMNANPSR1
SCHEMBL17552186 0.76 KMT2A (0.74) KMT2AMEN1LMNAKDM4ENPC1
SCHEMBL29831356 0.76 KMT2A (0.74) KMT2AMEN1LMNAKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210323924-A1 QUINOLINE SULFONAMIDES USEFUL TO TREAT DISEASE DAHL RUSSELL (US) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323924-A1 QUINOLINE SULFONAMIDES USEFUL TO TREAT DISEASE CLN6, NDUFS3, NDUFS2 TDP1 662/4885KMT2A 2019/4885MEN1 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.